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We read with a great interest the recently published retrospective propensity-matched analysis by Goksedef D et al 1 . The authors matched 58 patients: recombinant activated factor VII (rFVII)-treated group (n=29) and non-rFVII-treated group (n=29) 1 . Patients were compared on re-exploration, mortality, bleeding-related events, use of blood and blood products, length of intensive care unit stay, duration of hospitalization, and thrombotic complications 1 . We agree with authors' statement that strategies to prevent coagulopathic bleeding are essential for the successful management of patients undergoing complex aortic operations. However, we have few comments and suggestions for haemostatic management in such complex patients.
In our opinion, data regarding preoperative antiplatelet therapy management are lacking. We are interested whether matched patients were preoperatively exposed to antiplatelet therapy to rFVII administration 3 . In study by Chapman AJ et al 3 , group of patients treated with rFVII did have significantly higher rate of re-operation for bleeding, a two fold increase in the use of blood products, and, more frequently, had pulmonary complications 3 . In addition to, 3 Hacquard et al 4 reported 20% of patients with rFVII administration who continued to bleed severely despite rFVII therapy.
In our opinion, rFVII presents valuable therapeutic option in cases of intractable bleeding.
However, rFVII should be administered after other useful treatment modalities are exhausted.
For example, Spiess BD et al 5 reported thromboelastography guided hemostatic management to significantly reduce incidence of overall transfusion and mediastinal re-exploration due to excessive bleeding 5 . In addition to, the preliminary results of our research project under ClinicalTrials.gov Identifier: NCT01281397 (data not published, manuscript under preparation) showed modified rotational thromboelastometry and multiple electrode aggregometry results as predictors of excessive bleeding after cardiac surgery procedures.
Preoperative platelet function assessment and intraoperative hemostatic properties optimization guided by thromboelastometry can reduce proclivity to excessive bleeding, therefore, lead to diminished use of rFVII, with even better rFVII efficiency after functional hemostatic properties optimization prior to rFVII administration. Noteworthy, concomitant use of multiple electrode aggregometry and modified rotational thromboelastometry can help to define excessive bleeding as a surgical or a coagulopathic bleeding. rVII administration should follow previously mentioned pre-and intraoperative haemostatic optimization measures based on bedside suitable haemostatic monitoring devices with a short time frame from blood sampling to getting results. In our experience, such an algorithm can help in reducing both chest tube output and blood products transfusion requirements with only sporadically need for rFVII administration.
We congratulate the authors on their elegant and timely research.
